Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Akari Therapeutics Plc
AKTX | US
0.25
USD0
0%
AKTX | US
About Akari Therapeutics Plc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
0.25
Open
0.25
High
0.25
Low
0.25
Akari Therapeutics Plc a clinical-stage biopharmaceutical company focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities including paroxysmal nocturnal hemoglobinuria Guillain-Barré syndrome hematopoietic stem cell transplant-associated thrombotic microangiopathy and bullous pemphigoid as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London the United Kingdom.
View LessAKTX | US
Risk
61.2
Sharpe
-0.74
Luna's Score
43/100
Recommendation
Sell
Luna says (AKTX | US)
What's Working
Low Debt to Equity (< 0.25)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
70.8%1 month
61.2%3 months
100.9%6 months
120.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.07
Debt to equity
-0.27
Debt to assets
0.20
Ent. to EBITDA
-0.06
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-18.08M
MarketCap
3.05M
MarketCap(USD)
3.05M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-1.28K
Short ratio
2.26
Short perc.
0.41
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.05
Range1M
0.05
Range3M
0.25
Volumes: Market Activity
Rel. volume
0.32
Price X volume
17.87K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.06 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.07 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 100.91 | 72.80 | Riskier |
| Debt to Equity | -0.27 | -1.23 | Expensive |
| Debt to Assets | 0.20 | 0.25 | Cheaper |
| Market Cap | 3.05M | 3.66B | Emerging |
